To embed, copy and paste the code into your website or blog:
In this episode, AGG’s Food & Drug team leader, Alan G. Minsk, and team member, Genevieve M. Razick give an overview of FDA’s Office of Prescription Drug Promotion s (OPDP) enforcement of unlawful advertising in 2020.
Each month, we ll release a new podcast where different members of our Food and Drug practice and colleagues in other related life science teams will discuss issues and challenges they have encountered when assisting clients on business and legal issues.
Embed
Meet the New Boss, Same as the Old Boss: OPDP Issues Its First Letter of 2021 | Arnall Golden Gregory LLP jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
FDA COVID-19 responses and recommendations this week As the COVID-19 vaccines continue the early stages of circulation in the US, the agency keeps an eye on industry actions and offers advice to key players.
The first wave of US citizens are receiving COVID-19 vaccines in the country’s hospitals, clinics and, in one case, in their cars on a snowy highway. In the meantime, the US Food and Drug Administration (FDA) is maintaining its status as a source of advice for researchers, healthcare professionals, citizens and other affected entities.
The agency has updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures, and highlights on the FDA s response efforts.
To embed, copy and paste the code into your website or blog:
Arnall Golden Gregory LLP s Food & Drug Newsletter is a monthly update of legal and regulatory issues that affect the FDA-regulated community and highlights articles from members of our Food & Drug practice, as well as from colleagues in other related life science disciplines. We are thinking of all of you in these difficult times, and hope that you and your loved ones are healthy and safe.
Industry Insights
Not a Very Happy Thanksgiving for One Pharmaceutical Company: OPDP Issues an Untitled Letter For Unlawful Promotion
Instead of sending a turkey and cranberry sauce, in the spirit of 2020 where nothing is normal, the Food and Drug Administration’s Office of Prescription Drug Promotion (OPDP) made a different delivery this year for Thanksgiving. It sent an Untitled Letter to a pharmaceutical company for sending a misleading email to healthcare professionals about the prescription drug’s risks and efficacy. More >